Objective: To measure the association of B-type natriuretic peptide (BNP) and N-terminal fragment of BNP (NT-proBNP) with all-cause mortality after stroke, and to evaluate the additional predictive value of BNP/NT-proBNP over clinical information.
studies 10, 11 show that, although BNP has a statistically significant association with mortality and functional outcome, it does not add prognostic information to simple clinical variables. However, this new information should be carefully managed, because both studies were small and BNP-related peptides are important predictors of poor outcome in other diseases. 12, 13 Because there is still uncertainty about whether BNP could be useful in stroke practice to predict mortality, first we conducted a systematic review and a literature-based meta-analysis to examine the association of BNP/NT-proBNP levels with all-cause mortality after a cerebrovascular event. Second, we performed an individual participant data (IPD) analysis to further explore the role of natriuretic peptides and to assess whether their addition to clinical information could have additional predictive value and/or could improve mortality risk stratification.
METHODS Standard protocol approvals, registrations, and patient consents. Methods for this study were specified in advance and registered in the PROSPERO database (CRD42012003284). 14 We report it in reference to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 15 Eligibility criteria and search strategy. We included studies that reported original data and i) recruited patients with ischemic stroke, TIA, and/or hemorrhagic stroke; ii) measured BNP or NT-proBNP; and iii) recorded whether patients died during follow-up.
We searched MEDLINE and EMBASE databases up to October 26, 2012 without restriction (appendix e-1 on the Neurology ® Web site at www.neurology.org). Reference lists from identified articles and published reviews were hand-searched.
Two independent reviewers thoroughly checked titles and/or abstracts yielded by search and also screened potentially relevant articles in full text after removing duplicates. Disagreements were resolved by discussion.
Data collection. Two independent reviewers extracted data using a simple, standardized template. Appendix e-2 shows items included in that template. If data were missing, the corresponding author was contacted by e-mail.
Three independent reviewers assessed the quality of each included article using a 15-point quality score (appendix e-3), which does not apply for inclusion of the article in the meta-analysis. Corresponding authors from included articles were invited to participate sharing individual records using a preplanned dataset including baseline variables for IPD analysis (see appendix e-4).
Statistical analysis. STATA 10.0 (StataCorp, College Station, TX) and SPSS 15.0 (SPSS Inc., Chicago, IL) were used for statistical analyses, unless otherwise stated.
Literature-based meta-analysis. The strength of association of BNP/NT-proBNP with death was measured by weighted mean differences (WMDs) between death and survival groups with a random effects model. Cochrane Q and I 2 statistics measured heterogeneity. WMD not including zero on its confidence interval (CI) and with a t test p value ,0.05 were considered significant; forest plot summarized these size effects. We used meta-regression to adjust our study level meta-analysis for the potential confounders. We used Duval-Tweedie nonparametric "trim-and-fill" test 16 to assess publication bias.
IPD analysis.
A whole compiled database including all individual information was used as a unique cohort to perform a complete statistical analysis. We assessed publication bias with Duval-Tweedie test for both BNP and NT-proBNP separately. BNP and NT-proBNP levels had a nonnormal distribution (Kolmogorov-Smirnov test with p , 0.05), so we applied Mann-Whitney U or Kruskal-Wallis tests and reported median and interquartile range (IQR). Pearson x 2 test assessed differences among categorical variables. Correlations with stroke severity measured by NIH Stroke Scale (NIHSS) at admission and age were performed by Spearman rank.
Data from all different cohorts were normalized by standardized z scores in the unique database. We constructed forward stepwise multivariate logistic regression models with all clinical variables associated with mortality at p , 0.05 (baseline NIHSS score, age, and sex). Odds ratio (OR), 95% CI, and p value were given. Biomarker levels, using the highest quartile cutoff point, were added to the logistic regression model including clinical variables. To gain results consistency, we performed bootstrap calculation for OR and 95% CI in a random sample with replacement of the total number of patients, using a modified version of Car R-package. 17 The method of DeLong et al. 18 allowed us to compare the areas under the receiver operating characteristic curve (AUCs) from models including biomarkers with AUCs from clinical model only using MedCalc 12.3 software. Using R software (Hmisc and PredictABEL packages), net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indexes assessed the added value of the biomarker to the clinical model to predict mortality. 19 For the NRI test, prespecified clinically relevant thresholds of predicted risk (,10% and .90%) were used to calculate reclassification of patients.
In all cases, a p value ,0.05 was considered significant at a 95% confidence level. For multitesting, we applied Bonferroni correction.
RESULTS Study selection and characteristics. Our search strategy yielded 957 references, 20 of which were considered for full screening. Finally, 16 articles met inclusion criteria and were included in the meta-analysis (figure 1). Table 1 presents the characteristics of included studies. [7] [8] [9] [10] [11] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The quality of the 16 included articles was moderate (7 points, IQR 9-11; minimum 5, maximum 13). Only 25% of articles specified that measurement of biomarker was blind to clinical data; only one article reported sample size calculation (table e-1).
Synthesis of results from literature-based meta-analysis.
The included articles recruited a total of 3,498 stroke patients. Although BNP/NT-proBNP mean levels were higher in nonsurvivors than survivors, all studies showed large deviations (table 1) and a high heterogeneity between them (Q 5 274.92, I 2 5 94.5%, df 15, p , 0.001).
On average, BNP/NT-proBNP levels were 255.78 pg/mL higher in those patients who died (95% CI 105.10-406.47, p 5 0.001) (WMDs for each individual study and all-studies average are given in figure 2 ). This association was not affected by any of the study level confounders that were considered, including BNP vs NT-proBNP, stroke severity, age, plasma or serum measurement, time of sample collection, sex, and quality score. However, there exists uncertainty about the value of this result because study bias was detected by loss of significance when the Duval-Tweedie test was applied (pooled WMD 121.55 pg/mL, 95% CI 233.56 to 276.66, p 5 0.125).
Synthesis of results from IPD analysis. We obtained individual information from 2,258 stroke patients from 10 included articles. [8] [9] [10] [11] 20, 21, 24, 25, 27, 30 In the compiled dataset, we found NT-proBNP levels almost 10 ; p , 0.001). Therefore, analyses for the 2 peptides were performed separately. Neither BNP nor NT-proBNP changed the degree of association when the Duval-Tweedie test was applied. There was therefore no evidence of publication bias (data not shown). However, for BNP (with only 3 studies), the association with mortality did not reach statistical significance when WMDs were considered (pooled WMD 113.75 pg/mL, p 5 0.164).
We assessed the association of BNP and NT-proBNP levels with several demographic and clinical characteristics. Higher levels of both peptides were found in women (119 [ NT-proBNP) . Both BNP and NT-proBNP levels positively correlated with NIHSS score at admission (r 5 0.228, p , 0.001 for BNP; r 5 0.272, p , 0.001 for NT-proBNP) and age (r 5 0.340, p , 0.001; r 5 0.477, p , 0.001, respectively).
Because our systematic search was focused only on ischemic events, we further analyzed only ischemic stroke patients regarding mortality, and after exclusion of patients with hemorrhagic stroke or TIA, the sample size was 957 patients with BNP measurement and 880 patients for NT-proBNP. Table 2 presents demographic characteristics for each individual study and for pooled data. After data normalization, we divided patients into quartiles for both BNP and NT-proBNP and when the highest quartile was compared with the others, BNP was independently associated with poststroke mortality, giving a pooled adjusted OR of 2.30 (95% CI 1.32-4.01, p 5 0.003) after logistic regression adjustment for NIHSS score, age, and sex. NT-proBNP was also associated with mortality after stroke (adjusted OR 5 2.63, 95% CI 1.75-3.94, p , 0.001). These results indicate a double risk of death for those patients in the highest quartile for both peptides.
By using these cutoff points, only NT-proBNP showed a slight added value to model with clinical variables alone (NIHSS score, age, sex), showing an increase in AUC (p 5 0.029). Regarding discrimination improvement measured with the IDI index, both markers showed a small increase (0.018 points for BNP and 0.028 points for NT-proBNP). However, when reclassification of patients into predefined categories of risk of death was analyzed, again only the addition of NT-proBNP to simple clinical variables showed added value, classifying 8.1% of patients (NRI index; p 5 0.003) into more accurate risk categories than a model based on clinical variables alone (table e-2 and graphical representation in figure 3 ). Furthermore, for those patients who died, we explored BNP/NT-proBNP blood levels regarding the time that passed from stroke to death and no statistical difference was found (data not shown). The association with mortality was subanalyzed considering ischemic stroke etiologies. BNP/NT-proBNP levels were higher in cardioembolic strokes but only when alive patients were considered; we found differences in circulating levels between dead and alive patients in cardioembolic etiology, but also in lacunar (for BNP) and atherothrombotic (for NT-proBNP) strokes (figure e-1). Time of sample collection did not affect the association of BNP or NT-proBNP level with mortality (figure e-2).
We found similar results when nonnormalized data were used, for both predictive models (in which the highest quartile corresponds to BNP .216.40 pg/mL and NT-proBNP .1,453.45 pg/mL) and subanalyses (data not shown).
DISCUSSION Our meta-analyses confirmed the association of BNPs with mortality after stroke, independent of age, sex, and baseline neurologic impairment. However, although this association was statistically significant, these biomarkers did not lead to better prediction of death than clinical information alone.
The design used in this study has allowed us to perform a thorough analysis. Our literature-based metaanalysis performed after systematic review, with close to 3,500 patients, gave the statistical power needed to estimate whether a real association exists between BNP/NT-proBNP and death. Our results confirmed the presence of higher circulating BNP/NT-proBNP levels in those patients who died after a cerebrovascular event. 8, 9, 30 However, we found moderate quality of reporting (7 of 15 points), high heterogeneity among included studies (94.5%), and evidence of publication bias. Given this, the results of the literature-based meta-analysis should be carefully interpreted. Publication of negative studies has generally less acceptation and impact, and perhaps the lack of published negative studies in the field of biomarkers affects the results of meta-analyses; the publication of negative results may contribute first to give a more realistic point of view and second to save resources for other researchers.
A strong point in our design was the IPD analysis. We considered several covariates at patient level, being the least biased and most reliable means of addressing questions not resolved in independent studies. 31 We performed IPD analysis following a one-stage approach 32 (using the compiled database as a unique cohort). The IPD analysis showed both BNP and NT-proBNP as independent predictors of mortality after stroke, even after adjustment by typical confounders (such as NIHSS score, sex, and age). To have BNP/NT-proBNP levels in the highest quartile Table 2 Demographic characteristics of ischemic stroke patients of each included cohort and pooled data for IPD Data represent median (interquartile range) for NIHSS score and age. All other variables represented as percentage (sample size).
-5 information not available. Only ischemic stroke patients were considered.
Sample size of each cohort was given. Articles sharing cohorts were considered together in a unique database to avoid double counting of subjects.
doubled the risk of death after ischemic stroke compared with other quartiles.
Furthermore, one-stage IPD allows the performance of more complete statistical analysis in large cohorts (more than 2,000 patients in our case). We detected differences between BNP and NT-proBNP levels: NT-proBNP showed almost 10-fold higher concentration. This contrast might be attributable mainly to differences in the metabolism of these 2 peptides, which implies different half-lives, the longer corresponding to NT-proBNP, 33 and thus it justifies the analysis of each molecule separately.
Our main interest was to assess whether these biomarkers could improve the information given by clinical information alone by applying different statistical metrics, such as IDI and NRI. 19 In our IPD analysis, only NT-proBNP showed a marginal additional value over clinical data. Based on these results, we would not recommend the use of BNPs alone at the bedside to predict stroke outcome. Because currently there is not consensus about how much a marker must add to clinical models in terms of discrimination and reclassification improvements, with our results, only NT-proBNP might be considered in a future panel of prognostic biomarkers, including other known (interleukin-6, copeptin, etc.) or still unknown blood outcome biomarkers, in which each biomarker potentially increases discrimination and reclassification, reaching outstanding accuracy. Recently, the possibility has been suggested that the prognostic value of natriuretic peptides is dependent on stroke etiology. 28 We detected higher levels of both BNP and NT-proBNP in cardioembolic strokes only when alive patients were considered; moreover, circulating BNP and NT-proBNP were not exclusively associated with mortality in cardioembolic, but also in other causes of stroke. In addition, recently, high levels of BNP have been associated with cardioembolic etiology and with infarct volume in stroke patients, 34 reinforcing the heart-brain link and the suggestion that cardiovascular factors, in particular cardiac failure, adversely influence acute stroke outcome. 35 In our meta-analyses, we have focused on the relationship between BNP/NT-proBNP and stroke mortality and their role as useful biomarkers; therefore, the potential role of BNP/NT-proBNP in the detection of cardioembolic etiology, 36 mainly to define cryptogenic strokes, 37 needs further exploration and we suggest following a similar approach to the one presented here.
We believe that the implementation of these types of statistical analyses together with the proposal of minimal quality request (like other guidelines stated for publication 16 ) in biomarker studies would minimize the risk of bias and facilitate translation into clinical practice. Finding a way to predict poor outcome in those patients with stroke would provide information for patients and relatives, would help to evaluate the risk and benefits of acute treatments or inclusion into clinical trials, and would optimize the allocation into specialized stroke units.
Our meta-analysis presents some limitations. First, there were differences in methodology among the included articles, for both the method of analysis and time of blood collection, which could influence our results. Second, our systematic review focused on ischemic stroke, thus studies assessing mortality in hemorrhagic stroke or TIA were missed. Nevertheless, some of the included articles considered a mixed population, with ischemic as well as hemorrhagic strokes and/or TIA, which could not be separated in our literaturebased meta-analysis but were excluded in the IPD. Third, for subanalysis of mortality by stroke etiology, our conclusions should be carefully interpreted because of limited sample size: stroke etiology classification by TOAST (Trial of Org 10172 in Acute Stroke Treatment) was available in only half of the patients in the IPD analysis, including 278 patients with NT-proBNP measurement and 934 for BNP.
Finally, our IPD analysis, although considering several covariates, does not include some pathologies related to increased levels of BNP/NT-proBNP such as cardiopathies different from atrial fibrillation 38 or renal disease. 39 In addition, we could not access data regarding specific causes of death after stroke, which could influence the level of association of BNP/NT-proBNP.
In conclusion, both our literature-based meta-analysis and IPD analysis reinforce the role of BNP/NT-proBNP as independent predictors of all-cause mortality after stroke. However, these natriuretic peptides add minor predictive value to clinical information for the prediction of death. Their role in the clinical identification of an ischemic stroke of cardioembolic origin is uncertain and needs more research. 
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Comment:
Natriuretic peptides as predictive biomarkers of stroke outcome B-type natriuretic peptide (BNP), along with an inactive N-terminal peptide fragment (NT-proBNP), is secreted by cardiac ventricular myocytes in response to excessive myocardial stretching. The plasma half-life of these peptides is 0.3 and 2.0 hours, respectively, so a single measurement mostly reflects recent cardiac stress that may, for example, reflect sympathetic stimulation in response to acute stroke. Results from a variety of clinical studies indicate that these peptides may be useful as biomarkers for a variety of both cardiac and cerebrovascular events. In a carefully performed meta-analysis, García-Berrocoso and colleagues 1 evaluate the relationship of BNP and NT-proBNP levels with mortality following acute stroke. Although individuals in the highest quartile for either of the 2 peptides had twice the risk of death compared to the lower quartiles, only the NT-proBNP measures added slightly (additional 8.1% of patients) to the typical clinical measures for predicting stroke mortality, including age, sex, and NIH Stroke Scale score. The results do not go far enough to establish a relationship between the cause of death and the highest natriuretic levels. Some suggestive data from the ARISTOTLE trial indicate that cardiac death has an important role, but more careful studies that focus on the usefulness of measuring BNP or NT-proBNP within the first 24 hours after acute stroke, along with an analysis of the explicit causes of death, are needed. 2 
